Tempest Therapeutics Inc. (TPST)
NASDAQ · Healthcare
Tempest Therapeutics Inc. EBITDA 2013–2017
Tempest Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2013 to 2018. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Tempest Therapeutics Inc. ebitda for the quarter ending September 30, 2018 was -7.7 M, a 14.43% decrease year-over-year.
- Tempest Therapeutics Inc. ebitda for the twelve months ending September 30, 2018 was -25.6 M, a 62.17% decrease year-over-year.
- Tempest Therapeutics Inc. annual ebitda for 2017 was -82.7 M, a 4.95% increase from 2016.
- Tempest Therapeutics Inc. annual ebitda for 2016 was -78.8 M, a 11.40% increase from 2015.
- Tempest Therapeutics Inc. annual ebitda for 2015 was -70.7 M, a 48.92% increase from 2014.
- Tempest Therapeutics Inc. annual ebitda for 2014 was -47.5 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Tempest Therapeutics Inc. EBITDA — FAQ
Tempest Therapeutics Inc. (TPST) ebitda over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TPST's ebitda history?
The chart and table above show Tempest Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.